<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03368066</url>
  </required_header>
  <id_info>
    <org_study_id>20212</org_study_id>
    <nct_id>NCT03368066</nct_id>
  </id_info>
  <brief_title>Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?</brief_title>
  <official_title>Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hepatoadrenal syndrome has been well described in the literature and is known to be
      associated with poorer outcomes in both stable and critically ill cirrhotic patients. In
      chronic liver disease, adrenal (and more specifically cortisol) insufficiency is thought to
      be a byproduct of altered lipid metabolism that results in decreased HDL production and thus
      decreased delivery of cholesterol to the adrenal for subsequent corticosteroid production.
      Studies to date have implicated lecithin-cholesterol acetyltransferase (LCAT) as the key
      enzyme which is deficient in some cirrhotic patients, leading to an impaired ability to
      esterify cholesterol and thus a loss of normal cellular functioning and membrane stability.
      The investigators seek to quantify this LCAT deficiency in a cohort of cirrhotic patients and
      demonstrate its association with various abnormal physiologies associated with chronic liver
      disease, including spur cell anemia, low HDL levels, and adrenal insufficiency.

      Hospitalized cirrhotic patients at UVA that meet study eligibility criteria will be
      approached by a member of the study team to obtain consent for participation. If a patient
      agrees to become a study subject, they will have an approximate total of 35ml of blood drawn
      the following morning. Lab tests to be performed include: peripheral blood smear, lipid
      panel, free cortisol, cortisol binding globulin, serum cholesterol esters (surrogate for LCAT
      enzyme activity), and a standard-dose cortisol stimulation test. The latter involves blood
      drawn with the initial collection, administration of an intravenous 250mcg dose of synthetic
      ACTH, and then repeat small-volume blood draws at 30 minutes and 60 minutes later.

      Subjects will be classified as adrenally sufficient or insufficient on the basis of as
      standard-dose cortisol stimulation test. Variables of interest for comparison between the
      groups include MELD score, Child-Turcotte-Pugh (CTP) classification, high-density lipoprotein
      (HDL) levels, presence of spur cell anemia, serum cholesterol ester percentage (surrogate for
      LCAT enzymatic activity), cortisol binding globulin levels, and free cortisol levels.
      Student's t-test and Chi Square tests will be utilized to determine significance; a p &lt;0.05
      value will be used as our threshold for significance. If multiple factors are found to be
      significantly different in a univariate fashion between classification groups, a multivariate
      logistic regression analysis will be performed for adjusted analysis. The investigators will
      also seek to define any correlations between variables. Furthermore, the investigators will
      assess correlation between MELD score and serum cholesterol ester percentage, spur cell
      anemia, HDL levels, cortisol binding globulin levels, and free cortisol levels; similar
      correlate analysis will be done using CTP classification instead of MELD score.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cholesterol Esterification Deficiency</measure>
    <time_frame>24 hours</time_frame>
    <description>A percent quantification of serum cholesterol esterification will be measured via blood draw. Low values represent deficiency in esterification, which is a surrogate measure of lecthicin-cholesterol acetyltransferase (LCAT) enzymatic deficiency.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spur Cell Anemia</measure>
    <time_frame>24 hours</time_frame>
    <description>A peripheral blood smear will be obtained and assessed for presence of acanthocytes (spur cells).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adrenal Insufficiency</measure>
    <time_frame>24 hours</time_frame>
    <description>A baseline total cortisol level will be obtained and then patients will receive a standard-dose synthetic ACTH (Cosyntropin) stimulation test to assess for the presence of adrenal insufficiency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL Deficiency</measure>
    <time_frame>24 hours</time_frame>
    <description>Patients will have a lipid panel performed to assess for low HDL levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free Cortisol Deficiency</measure>
    <time_frame>24 hours</time_frame>
    <description>Patients will have their free cortisol levels measured to assess for deficiency.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Adrenal Insufficiency</condition>
  <condition>Cirrhosis</condition>
  <condition>Spur Cell Anemia</condition>
  <condition>Lecithin Acyltransferase Deficiency</condition>
  <arm_group>
    <arm_group_label>Hospitalized cirrhosis patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of cortisol stimulation test to assess for presence or absence of adrenal insufficiency</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cosyntropin</intervention_name>
    <description>Administer 250mcg cosyntropin to hospitalized cirrhosis patients to assess for the presence of adrenal insufficiency</description>
    <arm_group_label>Hospitalized cirrhosis patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;=18 years

          -  Diagnosis of cirrhosis

          -  Admission to hospital

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Prior enrollment in study (i.e. readmission)

          -  Prisoner

          -  Pregnancy

          -  Prednisone or Hydrocortisone use in last 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zachary Henry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia School of Medicine, Department of Medicine, Division of Gastroenterology &amp; Hepatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian J Wentworth, MD</last_name>
    <phone>973-943-6781</phone>
    <email>bw8xz@hscmail.mcc.virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zachary Henry, MD</last_name>
    <phone>434-243-2718</phone>
    <email>zhh6z@hscmail.mcc.virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian J Wentworth, MD</last_name>
      <phone>973-943-6781</phone>
      <email>bw8xz@hscmail.mcc.virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Zachary H Henry, MD</last_name>
      <phone>434-243-2718</phone>
      <email>zhh6z@virginia.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fede G, Spadaro L, Tomaselli T, Privitera G, Germani G, Tsochatzis E, Thomas M, Bouloux PM, Burroughs AK, Purrello F. Adrenocortical dysfunction in liver disease: a systematic review. Hepatology. 2012 Apr;55(4):1282-91. doi: 10.1002/hep.25573. Review.</citation>
    <PMID>22234976</PMID>
  </reference>
  <reference>
    <citation>O'Beirne J, Holmes M, Agarwal B, Bouloux P, Shaw S, Patch D, Burroughs A. Adrenal insufficiency in liver disease - what is the evidence? J Hepatol. 2007 Sep;47(3):418-23. Epub 2007 Jun 28. Review.</citation>
    <PMID>17629587</PMID>
  </reference>
  <reference>
    <citation>Triantos CK, Marzigie M, Fede G, Michalaki M, Giannakopoulou D, Thomopoulos K, Garcovich M, Kalafateli M, Chronis A, Kyriazopoulou V, Jelastopoulou E, Nikolopoulou V, O'Beirne J, Burroughs AK. Critical illness-related corticosteroid insufficiency in patients with cirrhosis and variceal bleeding. Clin Gastroenterol Hepatol. 2011 Jul;9(7):595-601. doi: 10.1016/j.cgh.2011.03.033. Epub 2011 Apr 8.</citation>
    <PMID>21545846</PMID>
  </reference>
  <reference>
    <citation>Fede G, Spadaro L, Tomaselli T, Privitera G, Piro S, Rabuazzo AM, Sigalas A, Xirouchakis E, O'Beirne J, Garcovich M, Tsochatzis E, Purrello F, Burroughs AK. Assessment of adrenocortical reserve in stable patients with cirrhosis. J Hepatol. 2011 Feb;54(2):243-50. doi: 10.1016/j.jhep.2010.06.034. Epub 2010 Sep 15.</citation>
    <PMID>21056503</PMID>
  </reference>
  <reference>
    <citation>Fede G, Spadaro L, Tomaselli T, Privitera G, Scicali R, Vasianopoulou P, Thalassinos E, Martin N, Thomas M, Purrello F, Burroughs AK. Comparison of total cortisol, free cortisol, and surrogate markers of free cortisol in diagnosis of adrenal insufficiency in patients with stable cirrhosis. Clin Gastroenterol Hepatol. 2014 Mar;12(3):504-12.e8; quiz e23-4. doi: 10.1016/j.cgh.2013.08.028. Epub 2013 Aug 24.</citation>
    <PMID>23978347</PMID>
  </reference>
  <reference>
    <citation>Tan T, Chang L, Woodward A, McWhinney B, Galligan J, Macdonald GA, Cohen J, Venkatesh B. Characterising adrenal function using directly measured plasma free cortisol in stable severe liver disease. J Hepatol. 2010 Nov;53(5):841-8. doi: 10.1016/j.jhep.2010.05.020. Epub 2010 Jul 17.</citation>
    <PMID>20739086</PMID>
  </reference>
  <reference>
    <citation>Jang JY, Kim TY, Sohn JH, Lee TH, Jeong SW, Park EJ, Lee SH, Kim SG, Kim YS, Kim HS, Kim BS. Relative adrenal insufficiency in chronic liver disease: its prevalence and effects on long-term mortality. Aliment Pharmacol Ther. 2014 Oct;40(7):819-26. doi: 10.1111/apt.12891. Epub 2014 Jul 30.</citation>
    <PMID>25078874</PMID>
  </reference>
  <reference>
    <citation>Tamer S, Cefle K, Palanduz S, Vatansever S. Rheological properties of blood in patients with chronic liver disease. Clin Hemorheol Microcirc. 2002;26(1):9-14.</citation>
    <PMID>11904466</PMID>
  </reference>
  <reference>
    <citation>Tamer S, Cefle K, Gokkusu C, Ademoglu E, Ozturk S, Vatansever S, Palanduz S, Guler K. Comparison of rheological parameters in patients with post hepatitic and alcoholic cirrhosis. Clin Hemorheol Microcirc. 2007;36(3):247-52.</citation>
    <PMID>17361026</PMID>
  </reference>
  <reference>
    <citation>Kakimoto H, Imai Y, Kawata S, Inada M, Ito T, Matsuzawa Y. Altered lipid composition and differential changes in activities of membrane-bound enzymes of erythrocytes in hepatic cirrhosis. Metabolism. 1995 Jul;44(7):825-32.</citation>
    <PMID>7616839</PMID>
  </reference>
  <reference>
    <citation>Alexopoulou A, Vasilieva L, Kanellopoulou T, Pouriki S, Soultati A, Dourakis SP. Presence of spur cells as a highly predictive factor of mortality in patients with cirrhosis. J Gastroenterol Hepatol. 2014 Apr;29(4):830-4. doi: 10.1111/jgh.12473.</citation>
    <PMID>24325340</PMID>
  </reference>
  <reference>
    <citation>Cooper RA, Diloy Puray M, Lando P, Greenverg MS. An analysis of lipoproteins, bile acids, and red cell membranes associated with target cells and spur cells in patients with liver disease. J Clin Invest. 1972 Dec;51(12):3182-92.</citation>
    <PMID>4640953</PMID>
  </reference>
  <reference>
    <citation>Miller JP. Dyslipoproteinaemia of liver disease. Baillieres Clin Endocrinol Metab. 1990 Dec;4(4):807-32. Review.</citation>
    <PMID>2082907</PMID>
  </reference>
  <reference>
    <citation>Kaiser T, Kinny-Köster B, Bartels M, Berg T, Scholz M, Engelmann C, Seehofer D, Becker S, Ceglarek U, Thiery J. Cholesterol esterification in plasma as a biomarker for liver function and prediction of mortality. BMC Gastroenterol. 2017 Apr 20;17(1):57. doi: 10.1186/s12876-017-0614-9.</citation>
    <PMID>28427335</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Zachary Henry, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Adrenal Insufficiency</mesh_term>
    <mesh_term>Lecithin Cholesterol Acyltransferase Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Cosyntropin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

